State Agency of Tuberculosis and Lung Diseases, Riga, Latvia.
Eur Respir J. 2010 Sep;36(3):584-93. doi: 10.1183/09031936.00003710. Epub 2010 Feb 25.
In the present study, we characterised drug-resistance patterns, compared treatment outcome between extensively and nonextensively drug-resistant tuberculosis (non-XDR-TB) cases, and assessed risk factors for poor outcome in a high-prevalence country that screens all TB patients for first-line anti-TB drug resistance. We reviewed drug susceptibility test results among all pulmonary TB cases in Latvia diagnosed from 2000-2004, as well as demographic and clinical characteristics, drug-resistance patterns, and treatment outcomes. During the 5-yr period, 1,027 multidrug-resistant tuberculosis (MDR-TB) cases initiated treatment. Among all cases, the proportion that experienced an outcome of cure or completion increased from 66.2 to 70.2% (p = 0.06 for linear trend). Among the 48 (4.7%) XDR-TB cases, 18 (38%) were cured, four (8%) died, three (6%) defaulted, and treatment failed in 23 (48%). In proportional-hazards analysis, characteristics significantly associated with poor outcome included XDR-TB, being retired, presence of bilateral cavitation, and previous MDR-TB treatment history for those aged ≥55 yrs. Overall, treatment success among all MDR-TB cases increased over time. Strategies to prevent transmission of XDR-TB and to further improve treatment outcome are crucial for the future of TB control in Latvia.
在本研究中,我们对耐药模式进行了特征描述,比较了广泛耐药和非广泛耐药结核病(non-XDR-TB)病例的治疗结果,并评估了在一个对所有结核病患者进行一线抗结核药物耐药性筛查的高流行国家中,预后不良的危险因素。我们回顾了 2000-2004 年期间拉脱维亚所有诊断为肺结核的病例的药物敏感性试验结果,以及人口统计学和临床特征、耐药模式和治疗结果。在 5 年期间,有 1027 例耐多药结核病(MDR-TB)患者开始治疗。在所有病例中,治愈或完成治疗的比例从 66.2%增加到 70.2%(线性趋势 p = 0.06)。在 48 例(4.7%)广泛耐药结核病(XDR-TB)病例中,18 例(38%)治愈,4 例(8%)死亡,3 例(6%)失访,23 例(48%)治疗失败。在比例风险分析中,与不良预后显著相关的特征包括 XDR-TB、退休、双侧空洞存在以及≥55 岁患者有既往 MDR-TB 治疗史。总体而言,所有 MDR-TB 病例的治疗成功率随时间推移而增加。预防 XDR-TB 传播和进一步提高治疗结果的策略对于拉脱维亚结核病控制的未来至关重要。